- /
- Supported exchanges
- / US
- / NTLA.NASDAQ
Intellia Therapeutics Inc (NTLA NASDAQ) stock market data APIs
Intellia Therapeutics Inc Financial Data Overview
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Intellia Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Intellia Therapeutics Inc data using free add-ons & libraries
Get Intellia Therapeutics Inc Fundamental Data
Intellia Therapeutics Inc Fundamental data includes:
- Net Revenue: 52 887 K
- EBITDA: -428 260 992
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Intellia Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -0.82
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Intellia Therapeutics Inc News
New
3 Gene Editing Stocks Retail Investors Are Watching After BioAdvance
Biotech just got a fresh policy tailwind, and the U.S. small and mid‑cap corner of the market suddenly looks a lot more interesting. With BIO's "BioAdvance" plan pointing to potential long term supp...
Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Intellia Therapeutics NTLA incurred a third-quarter 2026 loss of 91 cents per share, wider than the Zacks Consensus Estimate of a loss of 82 cents. The loss narrowed 1.1% from 92 cents per share in th...
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine lev...
Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.78 per share a year ago. These figures are...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.